Toxin-induced liver diseases lack effective therapies despite increased understanding of the role factors such as an overactive innate immune response play in the pathogenesis of this form of hepatic injury. Pentamidine is an effective antimicrobial agent against several human pathogens, but studies have also suggested that this drug inhibits inflammation. This potential anti-inflammatory mechanism of action, together with the development of a new oral form of pentamidine isethionate VLX103, led to investigations of the effectiveness of this drug in the prevention and treatment of hepatotoxic liver injury. Pretreatment with a single injection of VLX103 in the D-galactosamine (GalN) and lipopolysaccharide (LPS) model of acute, fulminant liver injury dramatically decreased serum alanine aminotransferase levels, histological injury, the number of terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL)-positive cells and mortality compared with vehicle-injected controls. VLX103 decreased GalN/LPS induction of tumor necrosis factor (TNF) but had no effect on other proinflammatory cytokines. VLX103 prevented the proinflammatory activation of cultured hepatic macrophages and partially blocked liver injury from GalN/TNF. In GalN/LPS-treated mice, VLX103 decreased activation of both the mitochondrial death pathway and downstream effector caspases 3 and 7, which resulted from reduced c-Jun N-terminal kinase activation and initiator caspase 8 cleavage. Delaying VLX103 treatment for up to 3 hours after GalN/LPS administration was still remarkably effective in blocking liver injury in this model. Oral administration of VLX103 also decreased hepatotoxic injury in a second more chronic model of alcohol-induced liver injury, as demonstrated by decreased serum alanine and aspartate aminotransferase levels and numbers of TUNEL-positive cells. Conclusion: VLX103 effectively decreases toxin-induced liver injury in mice and may be an effective therapy for this and other forms of human liver disease. (HEPATOLOGY 2017;66:922-935).
T oxin-induced hepatocyte injury is a common etiology of human liver disease. Despite an increased understanding of the pathophysiology of toxin-induced liver injury, therapies for the major forms of human hepatotoxicity, such as alcoholinduced liver disease, remain inadequate or nonexistent. Central to the pathogenesis of toxin-induced hepatocyte injury and cell death is hepatocellular damage from proinflammatory factors generated by the innate immune response. Inflammatory mediators of toxic liver injury include cytokines such as tumor necrosis factor (TNF) and reactive oxygen species that are injurious to toxin-damaged hepatocytes.
(1,2) Hepatotoxins also cause intestinal permeabilization (3, 4) which leads to increased delivery to the liver of gut bacterial products such as lipopolysaccharide (LPS) that stimulate hepatic macrophages to produce TNF and other factors that lead to liver injury. (5, 6) Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMDM, bone marrow-derived macrophage; GalN, D-galactosamine; IFNc, interferon-c; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; PARP, poly (ADP-ribose) polymerase; mRNA, messenger RNA; NF-jB, nuclear factor kappa B; NIAAA, National Institute on Alcohol Abuse and Alcoholism; PBS, phosphate-buffered saline; qRT-PCR, quantitative real-time polymerase chain reaction; SOD2, superoxide dismutase 2; TNF, tumor necrosis factor; TUNEL, terminal deoxynucleotide transferasemediated deoxyuridine triphosphate nick end-labeling.
Macrophage-produced TNF triggers hepatocyte apoptosis through TNF receptor 1. The cascade of events in this hepatocyte death pathway includes initiator caspase 8 activation, cleavage of the pro-apoptotic Bcl-2 family member Bid to tBid, and translocation of tBid to the mitochondrial membrane to trigger the release of apoptogenic factors such as cytochrome c that activate effector executioner caspases 3 and 7.
(7) The hepatic inflammatory response is therefore a potential therapeutic target to prevent activation of this death pathway in toxin-induced liver disease.
Pentamidine is an antimicrobial agent with wellestablished effectiveness and safety in several human protozoan diseases. (8) Pentamidine may have antiinflammatory properties that contribute to its efficacy against infectious pathogens. Pentamidine inhibits TNF production from LPS stimulation or Pneumocystis carinii infection in cultured alveolar macrophages, although the effect is partial. (9, 10) The absence of effects on TNF messenger RNA (mRNA) or intracellular protein levels in these studies suggested that the mechanism could be inhibition of secretion. (9) Pentamidine also decreases serum TNF and interleukin-6 levels after high-dose LPS injection in rodents. (11, 12) The effectiveness of pentamidine in other inflammatory responses has not been examined with the exception of the ability of the drug to mitigate dextran sodium sulphate-induced murine colitis. (13) The importance of inflammation in the pathogenesis of hepatotoxic liver injury, together with the development of a new, oral form of pentamidine isethionate VLX103, suggested that this drug might be effective in toxin-induced liver disease. To examine this possibility, we determined the effects of this drug on both acute fulminant liver injury from galactosamine (GalN)/LPS and a more chronic and milder alcohol model of hepatic injury. LPS stimulation of cytotoxic TNF has been implicated in the pathogenesis of liver injury in these models. (14, 15) VLX103 significantly decreased liver injury in both models. Mechanistic studies in the GalN/LPS model revealed that VLX103 moderately reduced TNF production and blocked caspase 8 and mitochondrial death pathway activation. VLX103 was protective even when given well after the initiation of GalN/LPS-induced hepatic injury. These findings indicate that VLX103 may be an effective therapy for toxin-induced human liver disease.
Materials and Methods

ANIMAL MODELS
C57BL/6J male and female mice were maintained under 12-hour light/dark cycles with unlimited access to food and water. Mice were fed a standard chow diet (PicoLab Rodent Diet 20 #5053; LabDiet, St. Louis, MO) at all times except during alcohol diet feeding. Mice were housed in static cages with a quarter-inch corncob bedding, individual water bottles, and cotton nestlets for enrichment. During alcohol diet feeding cages also contained a paper igloo. Littermates were used as vehicle-treated controls for all experiments.
GalN/LPS liver injury was induced in 10-to 14-week old male mice by an intraperitoneal injection of 100 mg/kg of LPS (Escherichia coli 0111:B4) and 700 mg/kg of D-galactosamine (Sigma-Aldrich, St. Louis, MO) dissolved in phosphate-buffered saline (PBS), as previously performed. (16) The GalN/LPS mortality studies were performed with an LPS dose of 10 mg/kg. For the pretreatment studies, an equal volume of PBS vehicle or pentamidine isethionate (VLX103; Verlyx Pharma Inc, Montreal, Canada) at a dose of 25, 40, or 50 mg/kg was injected intraperitoneally 30 minutes before GalN/LPS administration. For the posttreatment experiments, PBS or VLX103 at 40 mg/kg was injected at various times after GalN/ LPS.
ARTICLE INFORMATION:
Additional C57BL/6J male mice were injected with GalN plus TNF as described previously. (2) Mice were pretreated with PBS or VLX103 40 mg/kg intraperitoneally. At 30 minutes after this pretreatment, the mice were injected with GalN intraperitoneally, and then another 30 minutes later injected intravenously with 10 lg/kg of mouse recombinant TNF (PeproTech, Rocky Hill, NJ).
Studies of alcohol-induced injury employed a modified National Institute on Alcohol Abuse and Alcoholism (NIAAA) alcohol model. (17) Female 10-week old mice were administered 5 days of liquid control diet (Bio-Serv, Flemington, NJ; #F1259SP). Mice were then randomized to receive a 5% liquid ethanol diet (BioServ; #F1258SP), or pair-fed an equal caloric amount of the control diet. At this time the mice were started on a daily gavage of normal saline vehicle or VLX103 75 mg/ kg dissolved in normal saline. After 10 days of control/ ethanol diet feeding, a single gavage of ethanol 5 g/kg, or an equal volume and caloric intake of maltose dextrin, was administered to the mice. Mice were sacrificed 9 hours after gavage. All animal studies were approved by the Animal Care and Use Committees of the Albert Einstein College of Medicine and Emory University School of Medicine and followed the National Institutes of Health guidelines for animal care.
SERUM ASSAYS
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by commercial kits (TECO Diagnostics, Anaheim, CA).
HISTOLOGY
Hematoxylin and eosin-stained livers were evaluated for the amount of hepatic parenchyma with steatosis, apoptosis/necrosis or inflammation by a single pathologist in a blinded fashion on the following semiquantitative scale: 0, absent; 0.5, minimal; 1, mild; 1.5, mild to moderate; 2, moderate; 2.5, moderate to severe; 3, severe; and 4, markedly severe.
TERMINAL DEOXYNUCLEOTIDE TRANSFERASE-MEDIATED DEOXYURIDINE TRIPHOSPHATE NICK END-LABELING ASSAY
Terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL)-positive cells in liver sections were stained with the commercial kit DeadEnd Colorimetric System (Promega, Madison, WI). Under light microscopy, the numbers of TUNEL positive cells in 10 randomly selected high-power fields (magnification 3 200) were counted per liver section.
QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION
Total RNA was extracted from livers with the commercial kit RNeasy Plus (QIAGEN, Valencia, CA). Reverse transcription was performed with 1 mg of RNA in an Eppendorf Mastercycler (Hamburg, Germany) using a high-capacity complementary DNA reverse transcription kit (ABI, Foster City, CA). Annealing of primers was performed at 25 8C for 10 minutes, followed by elongation at 37 8C for 2 hours and inactivation of the enzyme at 85 8C for 5 minutes. Negative controls (no added transcriptase) were performed in parallel. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed in duplicate in a 7500 Fast Real-Time PCR System (ABI). The primer sequences in Supporting Table S1 were purchased from Integrated DNA Technologies (Coralville, IA). PCR was performed using Power SYBR Green Master Mix (ABI). Taq polymerase was activated at 95 8C for 10 minutes. The cycling parameters were denaturation at 95 8C for 30 seconds and extension at 60 8C for 1 minutes (for 40 cycles). Data analysis was performed using the 2 2DDCT method for relative quantification. Samples were normalized to glyceraldehyde 3-phosphate dehydrogenase.
CYTOKINE ASSAY
Cytokine levels were measured in serum samples with a multiplex kit (MCYTOMAG-70K; EMD Millipore, Billerica, MA) and Luminex xMAP Technology.
MACROPHAGE ISOLATION AND TREATMENTS
Bone marrow cells were isolated from untreated C57BL/6J mice and differentiated into bone marrowderived macrophages (BMDMs) as described previously. (18) BMDMs were pretreated with VLX103 at various concentrations for 1 hour, administered LPS (10 ng/ mL) and IFNc (100 ng/mL) (R&D Systems, Minneapolis, MN), and harvested at 12 hours for qRT-PCR.
Hepatic macrophages were isolated by Nycodenz gradient from untreated C57BL/6J mice and cultured as described previously. (19) Following overnight culture, the cells were pretreated with 10 lM VLX103 and 1 hour later treated with LPS and IFNc for harvest at 6 hours for qRT-PCR analysis.
PROTEIN ISOLATION AND WESTERN BLOTTING
Total protein and mitochondrial and cytosolic protein fractions were isolated from mouse liver and western blotting was performed as described previously. (20, 21) Membranes were probed with the fol- 
CASPASE 8 ACTIVITY
Caspase 8 activity was detected using a commercial fluorometric kit (Biovision, Milpitis, CA). Reactions were performed on 200 lg protein at 37 8C for 2 hours, and the samples were read in a fluorometer with 400-nm excitation and 505-nm emission filters.
TRIGLYCERIDE CONTENT
Hepatic triglyceride content was determined using a kit according to the manufacturer's instructions (Sigma) and values normalized to wet liver weight.
STATISTICAL ANALYSIS
Numerical results are reported as the mean 6 standard error and were derived from at least three independent experiments unless indicated otherwise. An unpaired Student t test was used to assess the significance between control and treated groups. Survival rates were compared by the Tukey multiple comparison test. Statistical significance was defined as P < 0.05.
Results
VLX103 PREVENTS LIVER INJURY FROM GalN/LPS
To examine the possible efficacy of VLX103 treatment in hepatotoxic liver injury, we determined whether pretreatment altered acute liver injury from GalN/LPS. C57BL/6J mice were injected with PBS vehicle or 25 or 40 mg/kg of VLX103 30 minutes prior to GalN/LPS. In C57BL/6J mice, GalN/LPS-induced liver injury was detectable at 4 hours and became severe by 6 hours, at which time lethality ensued. VLX103 pretreatment remarkably improved gross liver appearance after GalN/ LPS with an absence of the typical signs of hemorrhage (Fig. 1A) . Liver injury as determined by serum ALT levels was markedly decreased by both VLX103 concentrations (Fig. 1B) . Blinded, histological grading confirmed that VLX103 significantly reduced liver injury at 6 hours. (Fig. 1C,D) . Hepatocyte death was decreased as determined by significantly reduced numbers of TUNELpositive cells in VLX103-treated livers ( Fig. 2A,B) . VLX103 pretreatment therefore dramatically reduced liver injury from GalN/LPS.
VLX103 DECREASES GalN/ LPS-INDUCED MORTALITY
GalN/LPS triggers fulminant hepatic failure and death. To determine whether VLX103 merely delays liver injury or has a sustained protective effect that prevents mortality, survival was examined. PBS-pretreated mice all died within 12 hours of GalN/LPS, whereas VLX103-treated mice had a dose-dependent improvement in survival (Fig. 2C ). Mice pretreated with 25 mg/kg had a prolonged survival time but succumbed to death within 18 hours. Mice receiving the 40 or 50 mg/kg doses had a significantly improved survival, with 50% surviving with the highest dose (Fig.  2C ). Subsequent GalN/LPS studies were largely performed with the 40 mg/kg dose, which significantly blocked both liver injury and improved survival.
VLX103 REDUCES TNF INDUCTION
GalN/LPS liver injury is mediated by hepatocyte sensitization to cytotoxicity from LPS-induced macrophage cytokines, in particular TNF. (14, 22) To determine whether VLX103 was protective through TNF down-regulation, hepatic cytokine mRNA induction was assayed by qRT-PCR. Tnf mRNA levels after GalN/LPS treatment were decreased significantly by 47% at 1 hour, but unchanged at 2 and 4 hours in VLX103-treated mice (Fig. 3A) . VLX103 had no significant effect on Ifnc, Il-1b, or Il-6 mRNA levels (Fig. 3A) . Consistent with the mRNA findings, serum TNF levels were decreased significantly by 54% at 1 hour but unaffected at later times, and other cytokines were unchanged by VLX103 (Fig. 3B) . Decreased liver injury from VLX103 was therefore associated with an early decrease in TNF but not other proinflammatory cytokines. 
VLX103 DECREASES HEPATIC MACROPHAGE ACTIVATION AND TNF-INDUCED LIVER INJURY
The finding of decreased TNF production, together with reports that pentamidine is antiinflammatory in alveolar macrophages, (9, 10) suggested that VLX103 may directly suppress injurious proinflammatory hepatic macrophage activation. Cultured BMDMs were pretreated with increasing VLX103 concentrations and stimulated with LPS/IFNc for polarization into a proinflammatory M1 phenotype. (18) VLX103 failed to inhibit induction of the cytokine genes Tnfa, Il-1b, and Il-6 or M1-marker gene Nos2 (Fig. 3C) . In hepatic macrophages, however, the drug did inhibit proinflammatory activation as indicated by significant reductions in these same genes (Fig. 3D) . To determine whether TNF suppression is a mechanism of VLX103 hepatoprotection, drug effect was examined in GalN-sensitized mice cotreated with TNF.
VLX103 pretreatment partially but significantly reduced liver injury from GalN/TNF as determined by decreased ALT levels and TUNEL staining (Fig. 4A,B) .
FIG. 3. Effects of VLX103 on proinflammatory cytokines. (A)
Relative hepatic mRNA levels for Tnf, Ifnc, Il-1b, and Il-6 as determined by qRT-PCR in untreated mice (No tx) and PBS-and VLX103-pretreated mice at the indicated hours after GalN/LPS administration (*P < 0.01 compared with PBS-treated mice at the same time point; n 5 5-6). (B) Serum levels of TNF, IFNc, interleukin-1b, and interleukin-6 in untreated mice (Ø) and PBS-and VLX103-pretreated mice after GalN/LPS (*P < 0.05, **P < 0.0001 versus PBS-treated mice at the same time point; n 5 4-8). (C) BMDMs were not pretreated (0) or pretreated with 2.5-10.0 lM VLX103 and then left untreated (Con) or were treated with LPS/IFNc for 12 hours. Relative mRNA levels are shown for the genes indicated (n 5 3-9). (D) Relative mRNA levels for the indicated genes in cultured hepatic macrophages that were not pretreated (No tx) or pretreated with VLX103 and then not treated (Ø) or treated with LPS/IFNc for 6 hours (*P < 0.04, **P < 0.01 versus cells that did not receive VLX103; n 5 4-5).
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There was a trend to improved histology that did not reach statistical significance (Fig. 4C) . Although significant, the reduction in liver injury was markedly less than in the GalN/LPS model ( Figs. 1 and 2 ). Together these in vitro and in vivo findings demonstrate that a partial mechanism of VLX103's hepatoprotective effect is through inhibition of macrophage generation of TNF.
VLX103 BLOCKS ACTIVATION OF THE MITOCHONDRIAL DEATH PATHWAY
Hepatic toxicity from GalN/LPS occurs through the classical TNF death cascade of caspase 8-mediated Bid cleavage into tBid, which translocates to mitochondria to trigger cytochrome c release, effector caspase cleavage, and apoptosis. (7) Decreased TUNEL positivity suggested that VLX103 blocked TNFinduced apoptosis at some point along this pathway. Supportive of this idea was that VLX103 induced a dose-dependent decrease in the active, cleaved forms of effector caspases 3 and 7 at 6 hours after GalN/LPS (Fig. 5A ). Decreased caspase activity was confirmed by parallel findings of a dose-dependent reduction in cleavage of the caspase substrate PARP in VLX103-treated livers (Fig. 5A) .
Examination of the upstream mitochondrial pathway that triggers effector caspase cleavage revealed that VLX103 prevented its activation. Cytosolic tBid cleavage was blocked by VLX103 (Fig. 5B) , and tBid was virtually absent in mitochondria from VLX103-treated livers in contrast to the high levels in PBStreated mice (Fig. 5C) . As a result, the decrease in mitochondrial levels of cytochrome c (Fig. 5C ) and its release into the cytoplasm (Fig. 5B) were blocked in VLX103-treated mice. VLX103 therefore decreased apoptosis from GalN/LPS by mitigating mitochondrial death pathway and effector caspase activation.
VLX103 INHIBITS CASPASE 8 ACTIVATION
The marked decrease in mitochondrial death pathway activation suggested that VLX103 blocked hepatocyte death from GalN/LPS through inhibition of upstream caspase 8. Increased hepatic caspase 8 activity was detectable in PBS-treated mice at 2-6 hours after GalN/LPS treatment, but activity was decreased significantly at 4 and 6 hours by VLX103 (Fig. 6A) . Immunoblots confirmed that cleavage of caspase 8 to its active p18 form was decreased by VLX103 (Fig.  6B ). VLX103 therefore blocked caspase 8 activation, preventing Bid cleavage and mitochondrial death pathway activation that induce liver injury from GalN/ LPS.
TNF induction of hepatocyte caspase 8 activation is down-regulated by NF-jB, which curtails JNK phosphorylation. (21, 23) Examination of VLX103's effect on NF-jB signaling revealed that hepatic NF-jB activation occurred in both vehicle-and VLX103-treated mice as indicated by nuclear translocation of the phosphorylated p50 and p65 NF-jB subunits (Fig. 6C) . Levels of proteins that mediate hepatocyte resistance to TNF-dependent apoptosis such as cIAP1, cIAP2, SOD2, and Bcl-X L (7) were unaffected by VLX103 (Fig. 6D) . Despite the absence of an effect on NF-jB activation, VLX103 did markedly reduce levels of JNK activation, as indicated by decreased levels of phosphorylated JNK (Fig. 6E ).
VLX103 TREATMENT IS HEPATOPROTECTIVE POST-GALN/LPS ADMINISTRATION
For human liver disease, a therapeutic agent must be effective when administered after the onset of injury. We therefore determined whether VLX103 was hepatoprotective when administered after the initiation of GalN/LPS-induced injury. Although the greatest reduction in hepatic injury was afforded by VLX103 pretreatment, administration of this agent even at 2 and 3 hours after GalN/LPS significantly decreased liver injury. Serum ALT levels were reduced 75% by VLX103 given 2-3 hours after GalN/LPS (Fig. 7A) . TUNEL staining revealed a diminished but still significant decrease in hepatocyte death with VLX103 posttreatment (Fig. 7B ). VLX103 treatment 3 hours postGalN/LPS was highly effective in reducing cytosolic (Fig. 7C ) and mitochondrial levels of tBid, as well as mitochondrial cytochrome c loss (Fig. 7D) and release into the cytosol (Fig. 7C) . As a result, VLX103 posttreatment was highly effective in decreasing caspase 3 and 7 and PARP cleavage (Fig. 7E) . These findings indicate that VLX103 is therapeutic when administered significantly after GalN/LPS, even immediately before the onset of liver injury.
VLX103 PROTECTS AGAINST ALCOHOLIC LIVER INJURY
The therapeutic potential of oral VLX103 was examined in a more chronic and nonlethal modified NIAAA model of alcoholic liver disease. (17) Mice received a daily gavage of vehicle or VLX103 (75 mg/ kg) during 10 days of ethanol feeding, and then a binge dose of alcohol by gavage for analysis 9 hours later. VLX103 decreased hepatic triglyceride content by 34% (Fig. 8A) . In vehicle-treated mice, serum ALT and AST levels increased 3.3-and 2.5-fold, respectively, but levels were significantly decreased 50% by VLX103 (Fig. 8B,C) . Histologically, there was a nonsignificant trend to decreased steatosis, but differences were not detected in injury or inflammation, as the levels of both histological features were low with alcohol feeding (Fig. 8D) . A reduction in liver injury was confirmed by findings of a significant decrease in TUNEL-positive cells with VLX103 (Fig. 8E) in association with decreased proinflammatory cytokine gene expression (Fig. 8F) . Oral VLX103 was therefore effective in decreasing hepatotoxic liver injury from alcohol. 
Discussion
Inflammatory mediators such as TNF promote hepatocellular injury in alcoholic hepatitis, ischemia/ reperfusion, nonalcoholic steatohepatitis, viral hepatitis and fulminant hepatic failure. (7) Anti-inflammatory therapies might therefore be effective in liver diseases. However, the results of studies to date, including investigations blocking TNF, have been disappointing. Pentamidine is an antimicrobial agent that has been used safely in humans for many years. (8) The mechanism of pentamidine's antimicrobial effect is unknown. In vitro macrophage and rodent studies have suggested that one mechanism of the drug's actions may be an anti-inflammatory effect. (9) (10) (11) (12) (13) In the present study, we demonstrate for the first time that pentamidine significantly reduces hepatotoxic liver injury. A particularly significant finding from these studies is that VLX103 reduced GalN/LPS injury when administered after cell death initiation and induced lasting hepatoprotection that dramatically increased survival.
Consistent with previous studies in nonhepatic cells, (9) (10) (11) VLX103 decreased proinflammatory cytokine production. Hepatic TNF protein secretion was reduced in response to GalN/LPS, an effect that occurred in part at the transcriptional level, in contrast with previous in vitro studies indicating that pentamidine acts posttranslationally. (9, 24) TNF inhibition was partial with a 54% decrease at 1 hour after GalN/LPS and no effect at later times. The reduction in TNF may reflect a direct anti-inflammatory effect on macrophages as VLX103 inhibited hepatic macrophage activation in vitro including TNF induction. Interestingly, this finding was specific for hepatic macrophages, as VLX103 exerted no anti-inflammatory effect on BMDMs. This discrepancy raises the interesting therapeutic possibility that VLX103 specifically targets tissue macrophages without systemic depression of the innate immune response, thereby potentially avoiding infectious complications that have doomed anti-TNF therapy in human alcoholic liver disease. The effects of VLX103 on cultured hepatic macrophages were different than with GalN/LPS, as Il-1b and Il-6 were inhibited in vitro but not in the GalN/LPS mouse model. However, all of these cytokines were decreased by VLX103 in the in vivo alcohol model. Suppression of macrophage activation may have been less complete in the acute fulminant GalN/LPS model because of more extensive macrophage stimulants that partially overrode the anti-inflammatory effects of VLX103.
Alternatively, pentamidine binds LPS, (25) and VLX103 may inactivate LPS, thereby removing the stimulus for immune cell activation through TLR4 signaling. The fact that induction of Il-1b and Il-6 was unaffected by VLX103 in GalN/LPS, however, indicates that the drug did not block the LPS initiation of inflammation. Although the reduction in TNF may partially explain VLX103's protective effects, this mechanism cannot be the sole mode of action, because VLX103 treatment delayed to 3 hours after GalN/LPS-a time long after LPS has triggered a proinflammatory cytokine response-was still highly effective. Consistent with the fact that an anti-TNF effect in part explains the efficacy of VLX103 is that delayed VLX103 administration was less effective than pretreatment. Findings of a significant but reduced protective effect of VLX103 in GalN/TNFinduced injury also support the conclusion that the hepatoprotective mechanisms of this drug are only partially due to TNF inhibition. VLX103 must therefore act through mechanisms other than direct anti-inflammatory effects on immune cells and/or LPS neutralization in this model of acute fulminant injury.
VLX103 also reduced liver injury from a chronic plus acute binge alcohol model. This study is notable for establishing drug efficacy in a second hepatotoxic injury model and for demonstrating the effectiveness of oral VLX103 in liver injury. In contrast to GalN/LPS, in the alcohol model VLX103 had a generalized antiinflammatory effect, as indicated by a significant reduction in multiple cytokines. These results are concordant with the generalized in vitro anti-inflammatory effect of VLX103 on hepatic macrophages. The different in vivo findings may be the result of a greater reduction in LPS due to the use of oral VLX103 in the alcohol model as opposed to intraperitoneal delivery for GalN/LPS. The reduction in triglycerides might be secondary to this anti-inflammatory effect as cytokines such as TNF promote excessive lipid accumulation. (26) VLX103 also inhibited the hepatocyte extrinsic death pathway that is triggered by TNF. TNF-induced apoptosis results from type 1 TNF receptor binding which recruits a complex that triggers initiator caspase 8 activation by self-cleavage. Caspase 8 cleaves Bid into tBid which with other Bcl-2 family members initiates permeabilization of the outer mitochondrial membrane and release of proteins such as cytochrome c that activate effector caspases 3 and 7. (7) In the GalN/LPS model, VLX103 decreased activation of all elements of this pathway. That VLX103 affected initial caspase 8 cleavage suggests that the drug acts at this level of the cascade. However, the reduction in caspase 8 cleavage was only partial, whereas inhibition of the mitochondrial FIG. 8. VLX103 blocks alcohol-induced liver injury. (A) Hepatic triglyceride content in mice that received a control (CD) or ethanol diet (ED) with normal saline (NS) or VLX103 (75 mg/kg) by gavage (*P < 0.01 versus ethanol diet-fed, normal saline-treated mice; n57-9). Serum ALT (B) and AST (C) levels in the same mice (*P < 0.005 versus ethanol diet-fed, normal saline-treated mice; n 5 7-9). (D) Histologic grades of steatosis (Ste), inflammation (Inf), and injury (Inj) (n 5 5-6). (E) Numbers of TUNEL-positive cells (*P < 0.004 versus ethanol diet-fed, normal saline-treated mice; n 5 7-9). (F) Relative hepatic mRNA levels for Tnf, Ifnc, Il-1b, and Il-6 (*P < 0.02 versus ethanol diet-fed, normal saline-treated mice; n 5 3-4). death pathway as measured by cytochrome c release was virtually complete, suggesting that either partial caspase 8 inhibition was sufficient to achieve this effect or VLX103 acted upon several steps in the death cascade. Supportive of the effect being strictly at the level of caspase 8 inhibition is that caspase 8-dependent Bid cleavage was almost totally blocked.
The mechanism of caspase 8 activation from GalN/ LPS is sustained JNK over activation. (21, 23, 27) VLX103 led to a reduction in activated, phosphorylated JNK in response to GalN/LPS indicating that the drug blocked caspase 8 activation through this mechanism. TNFinducible NF-jB signaling down regulates JNK activation, (23) but NF-jB activation and levels of protective proteins were unaffected by VLX103. This finding suggests that VLX103 is a direct JNK inhibitor, but studies in cultured hepatocytes revealed no direct inhibitory effect of this compound on JNK phosphorylation (data not shown). Elucidation of the effects of VLX103 on JNK signaling will require additional study.
The findings demonstrate a therapeutic effect of pentamidine in toxin-induced liver injury that likely occurs through several mechanisms. The ability of VLX103 to have beneficial effects on both immune cell cytokine production and hepatocellular death pathways indicates a possible unique therapeutic strength of the drug and suggests that VLX103 may have more widespread applications than toxin-induced liver injury. Supportive of this concept are that VLX103 reduced liver injury in a mouse model of nonalcoholic fatty liver disease. (28) In light of these findings, and the established human safety profile of pentamidine, VLX103 warrants further investigation as a possible therapy in human liver disease.
